Among all peripheral arterial diseases, lower extremity arterial disease is a serious condition in subjects with type 2 diabetes mellitus, associated with important disability, cardiovascular risk, and socio-economic burden. Patients with both conditions generally display poorer prognosis of affected limbs compared with non-diabetic subjects, leading to increased rates of adverse limb events including amputations. Nonetheless, awareness on lower extremity arterial disease remains somehow suboptimal in the diabetic population, partly related to an atypical clinical presentation in several cases. A regular and appropriate screening for lower extremity arterial disease in patients suffering from type 2 diabetes mellitus is therefore recommended. Affected subjects should receive optimal medical treatment including careful management of the different cardiovascular risk factors through a healthy lifestyle, a regular and structured physical activity, the administration of lipid-lowering, antidiabetic drugs, and (when indicated) antihypertensive and antithrombotic drugs. This review aims to outline current evidence about lower extremity arterial disease in patients with type 2 diabetes mellitus, in order to elucidate its epidemiology, pathophysiology, screening and diagnosis, and management options.
Introduction
Lower extremity arterial disease (LEAD), resulting from a partial or complete obstruction of one or more arteries of lower limbs, is a condition associated with consistent disability in terms of both clinical symptoms and functioning. Besides emerging evidence of factors like ethnicity, genotype, poverty and industrialization, and infection, LEAD development has been traditionally associated with several classical cardiovascular (CV) risk factors, including advanced age, tobacco smoking habit, arterial hypertension, dyslipidaemia and type-2 diabetes (T2DM). 1 In particular, LEAD is associated with T2DM, and patients suffering from both conditions have consistently worsening quality of life and prognosis compared with non-diabetic subjects with LEAD. Projected trends from 2013 to 2035 indicate that the number of patients with T2DM will globally increase from 382 to 592 m, 2 related to the worldwide epidemic of associated obesity. Consequently, a higher proportion of LEAD cases associated with T2DM is expected in the near future, at least in Western countries.
Despite its burden on public health, physicians' awareness of LEAD remains somehow scarce in patients with concomitant T2DM. Only a few randomised controlled trials (RCTs) and reviews have focused specifically on this clinical scenario. This comprehensive, narrative review aims to outline current evidence about this pathological association, in order to elucidate its epidemiology, pathophysiology, screening and diagnosis, and management options.
Epidemiology and risk factors
It is estimated that LEAD affects over 200 m people worldwide, including 40 m people living in European countries. 3 The exact prevalence of LEAD in people suffering from T2DM is difficult to establish because of several factors, such as the absence of specific symptoms, the reduction in pain sensitivity due to peripheral neuropathy, and inadequate screening in several cases. Compared to the general population, LEAD has been found to be 2-4 times more frequent in subjects with T2DM. 4 In the ADVANCE trial, including a diabetic population with a mean age of 65.7 years and a median duration of T2DM of seven years, baseline prevalence of LEAD was estimated at 4.6% when LEAD was defined as chronic foot ulceration due to arterial insufficiency, need for peripheral revascularization procedure, or lower-limb amputation of at least one toe. 5 Percentages rose up to 13.6% when the LEAD definition included abnormal ankle-brachial index (ABI). 6 The risk of LEAD grows in parallel with T2DM severity, its duration, poor glucose level control and insulin use. It has been estimated that the risk of LEAD increases by 26% for every 1% increase in haemoglobin-A1c (HbA1c) level. 7 The UKPDS showed a prevalence of LEAD of 1.2% and 12.5% at diagnosis of T2DM and after 18 years from diagnosis, respectively. 8 In general, all population studies are concordant in presenting T2DM as a significant risk factor for LEAD even after multiple adjustments for potential confounders. 4 In a population study performed in the USA, it was estimated that the proportional attributable fraction of T2DM for incident LEAD was 14%. 9 Microvascular complications of T2DM, mainly macroalbuminuria (defined as urinary albumin to creatinine ratio > 300 mg/g), and diabetic retinopathy (defined as requirement of retinal photocoagulation therapy, proliferative retinopathy, macular oedema or diabetes-related blindness), also emerged as independently associated with an increased risk of LEAD. 10 
CV burden
Compared to non-diabetic counterparts, the diabetic patients with LEAD are at increased risk of chronic limb-threatening ischaemia (CLTI), which is the most severe presentation of the disease. In the European Study Group on Diabetes and the Lower Extremity study, LEAD was present in 49% of subjects with diabetic foot, while one-third of participants had either LEAD or infection. 11 Subjects with LEAD and T2DM are also at higher risk of major adverse limb events (MALEs), including lower limb amputation (LLA) and acute limb ischaemia and more than 50% of all LLAs occur in people with T2DM.
LEAD also represents an indicator of systemic atherosclerosis in other vascular territories, such as the coronary, carotid and cerebrovascular arteries, which may eventually result in the occurrence of major adverse cardiac events (MACEs), such as myocardial infarction, stroke and CV death. This is particularly the case of symptomatic patients, independently of the presence of T2DM, in whom the rates of MACEs were estimated at 4-5% per year. 12, 13 
Pathophysiological mechanisms
The natural history of LEAD is somewhat similar in patients with or without T2DM. However, in the diabetic population, the increased predisposition to LEAD involves some peculiar pathways, such as overproduction of advanced glycation end-products (AGEs), increased oxidative stress and inflammation. Furthermore, the abnormal metabolic state in T2DM patients contributes to the aggravation of atherothrombosis, mainly through pathological activation of coagulation mechanisms, platelet dysfunction and plaque rupture, which accelerate LEAD progression ( Figure 1 ).
T2DM is a metabolic disease characterised by chronic hyperglycaemia, which promotes formation of AGEs, a series of molecules resulting from the interaction between the ketone group of the glucose molecule, or aldehydes, and the amino groups of proteins. Signalling-transducing receptors for AGEs (RAGEs) are expressed in several cell types, and increased RAGE expression has been documented in both chronic inflammation and T2DM. 14 The importance of the interaction between RAGEs and their ligands in vascular disease has been extensively studied, and a recent prospective analysis on 146 patients demonstrated its role also in the development of LEAD. 15 In fact, the binding of AGEs to endothelial RAGEs induces reactive oxygen species (ROS) production, which leads to endothelial dysfunction through inactivation of endothelium-derived nitric oxide (NO) and uncoupled endothelial NO synthase (eNOS) activity. This interaction stimulates the expression of some proinflammatory cytokines, like tumor necrosis factor (TNF)-a, interleukin (IL)-1a, IL-6, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and E-selectin, which contribute to the vascular damage. 16 A recent study demonstrated that AGEs are also capable of promoting apoptosis and inhibiting the migration of endothelial progenitor cells, 17 thus suggesting a pathological role of such molecules in impaired reparative angiogenesis in ischemic extremities.
T2DM-related hyperglycaemia induces oxidative stress with overproduction of highly reactive molecules, such as ROS, and reactive nitrogen species (RNS). Current evidence supports the role of oxidative stress in vascular diseases, including LEAD. 18 Of note, T2DM is also associated with a state of chronic inflammation, characterised by increased levels of proinflammatory cytokines, such as C-reactive protein (CRP), TNF-a and IL-6, which further contribute to the development of LEAD. 19 Low-density lipoprotein cholesterol (LDL-C) and ROS levels are both increased in the diabetic population, thus resulting in enhanced lipid peroxidation and oxidative modification of LDL-C (oxLDL-C). 20 Additionally, lectin-like oxLDL-C receptor 1 (LOX-1) is overexpressed in T2DM, and the interaction between oxLDL-C and LOX-1 enhances ROS production by activating the enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. 21 Interestingly, serum LOX-1 was found to be associated with the ABI, thus potentially representing a novel marker for LEAD in subjects suffering from T2DM. 22 T2DM may be also associated with increased risk of thrombus formation. In particular, several prothrombotic factors, such as plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (vWF) and fibrinogen are upregulated in this condition, and may be involved in LEAD progression. 23 Compared to subjects with LEAD alone, those with LEAD and T2DM may be more prone also to plaque rupture. In fact, the expression of YKL-40, a molecule that is secreted by macrophages in atherosclerotic lesions and is involved in plaque rupture, was found to be enhanced in patients with LEAD, and even more so in those with concomitant T2DM. 24 Matrix metalloproteinases (MMPs) contribute to plaque vulnerability via degradation of extracellular matrix proteins, and their plasma levels correlate with LEAD development and severity. Intriguingly, several studies demonstrated that AGEs, CRP and oxLDL promote MMP-9 production, thus increasing the risk of degradation of the fibrous cap over the atherosclerotic plaque. 19 
Screening and diagnosis Clinical examination
Clinical LEAD is often preceded by a long phase of subclinical progression of the disease where patients are already at increased risk of CV events. Besides, the symptoms are more often atypical, and may suddenly express a severe form. For all these reasons, patients with T2DM should undergo annual clinical screening for LEAD. An exhaustive interview should look for history of intermittent claudication, ischaemic rest pain, leg fatigue or decreased walking speed.
Since sensory neuropathy may hide symptoms of LEAD, atypical pain has to be systematically investigated as well. The clinical presentation of LEAD may be assessed according to the Leriche and Fontaine or Rutherford classifications (Tables 1 and 2) . Physical examination has to focus mainly on the inspection of the feet, the evaluation of skin temperature of the extremity and the palpation of distal arteries (i.e. posterior tibial and dorsalis pedis pulses). Nonetheless, pulse palpation has a weak diagnostic performance, and the dorsalis pedis pulse can be absent even if there is no vascular disease. Lack of both distal pedis and tibial posterior pulses may improve the performance of the test.
ABI test
The ABI is the first-line diagnostic test in patients with symptoms or signs of LEAD. It should be considered also in asymptomatic patients at increased risk of LEAD, particularly in case of adjunctive CV risk factors (age > 50 years, smoking, hypertension and hyperlipidaemia), a history of other vascular territories, heart failure or chronic renal failure, as well as a duration of T2DM > 10 years ( Figure 2 ). Screening is reasonable in this context to improve risk stratification, preventive care and medical management of patients at increased risk of both MACEs and MALEs. 25 It is defined as the ratio of systolic blood pressure (SBP) at the ankle over the SBP in the upper arm. It is considered abnormal when 0.90. One specific presentation of artery disease at the distal level is medial arterial calcification (MAC), leading to incompressible arteries and abnormally increasing values of ABI over 1.40. In this case, additional assessment is necessary to look for occlusive disease underneath, as MAC is often associated with atherosclerosis. LEAD can be detected by analysis of Doppler waveforms, or measurement of the toe-brachial index (TBI). TBI is abnormal when < 0.70. A decrease of ankle SBP by > 30 mm Hg or an ABI decrease of > 20% following the effort treadmill test are diagnostic for LEAD. 26 In the case of CLTI, ABI (when measurable), TBI and the transcutaneous pressure of oxygen (TcPO2) are indicated for the assessment of malperfusion severity. TcPO2 may be used to estimate the likelihood of wound healing or the requirement and type of amputation in this setting.
The treadmill test could be helpful when ischaemic origin of limb pain is uncertain, such as in case of typical claudication but normal or borderline ABI at rest. 26 In order to study the peripheral blood flow during exercise in patients with T2DM and LEAD, several alternatives have been investigated, including contrast enhanced ultrasound, near infrared spectroscopy, whole-body 201 Tl scintigraphy and thermodilution. Nonetheless, further research is needed to establish the precise role of such imaging techniques in real practice.
Ultrasound and other imaging methods
Several imaging techniques are currently available to confirm the diagnosis of LEAD in patients with T2DM, including duplex ultrasound (DUS), computed tomography angiography (CTA), magnetic resonance angiography (MRA) and digital subtraction angiography. DUS is the first-line imaging for peripheral arterial diseases. DUS is a simple and non-invasive technique providing anatomical and haemodynamic assessment of the vessels, and is capable of assessing vein quality for bypass procedures and it is the test of choice for routine follow-up after revascularization. DUS has a sensitivity of 85-90% and a specificity > 95% to detect arterial stenosis > 50%. 27 It is particularly accurate in localising and classifying aorto-iliac occlusive disease, while its performance decreases in case of distal lesions (i.e. of the foot). DUS performance depends on operator experience and good training is mandatory.
Certain limitations exist with other imaging techniques such as CTA and MRI, due to the potential Figure 2 . Initial diagnostic workup for lower extremity arterial disease (LEAD) in patients with type 2 diabetes mellitus (T2DM). The ankle-brachial index (ABI)-based screening should be performed once when diabetes is diagnosed, and then after 10 years of diabetes if initial examination was normal (can be considered after five years of diagnosis in selected cases at high risk for LEAD). Patients should be assessed every year for symptoms, and pulses should be also checked. In the case of borderline results (e.g. 0.89) repeat the measurement and average results to increase accuracy. If the toe-brachial index (TBI) is available, this can be done in conjunction with the ABI.
(ESC) guidelines, 25 'critical' implies that all patients have to undergo revascularization urgently to avoid limb loss, while some patients with CLTI may actually receive conservative treatment for long periods. Moreover, the risk of amputation does not depend exclusively on the severity of ischaemia, but also on the presence of a wound and infection. In this setting, the wound ischaemia and foot infection (WIFI) classification may be a useful tool, providing risk stratification based on the severity of the wound, ischaemia and foot infection (Table 3 ). 30 
Therapeutic strategies
The management of LEAD in patients with T2DM requires a multidisciplinary team, including vascular physicians and surgeons, diabetologists, infectious disease specialist, cardiologist, radiologist, rehabilitation specialist and podiatrist.
Overall, the available therapeutic measures aim to improve the clinical status of patients in terms of both symptoms and function. They also seek at limiting the atherosclerotic progression in affected vessels.
Conservative treatment
Physical activity and diet. Physical activity has a positive effect on many CV risk factors, including blood pressure (BP), LDL-C levels, body weight and insulin sensitivity. 31, 32 In patients with symptomatic LEAD, exercise therapy is particularly effective, being able to improve symptoms, quality of life and maximum walking distance. In the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) study, the authors showed a greater improvement in the maximum walking distance at six months in patients performing supervised exercise therapy, as compared to those undergoing arterial revascularization. However, the difference in maximum walking time at 18 months was not statistically different between the groups. 33 In addition, in 30 RCTs including 1816 subjects with stable intermittent claudication, exercise therapy increased the maximum walking distance by approximately five minutes on the treadmill. 34 Pain-free and maximal walking perimeters increased by 82 m and 109 m, respectively, with benefits persisting for up to two years.
Eating habits also influence CV risk. Most of the evidence on the relationship between nutrition and in CV disease is based on observational studies, while RCTs are rare. Among those, a study by Maiorino et al. on diabetic patients found that, compared with a low-fat diet, a long-term Mediterranean diet was associated with an increase in circulating endothelial progenitor cells levels and prevention of the progression of subclinical atherosclerosis, defined in terms of carotid intima-media thickness. 35 The Mediterranean diet should be thus encouraged in all subjects with LEAD and concomitant T2DM.
Anti-diabetic treatment. Optimal management of glycaemic levels should be encouraged in every patient with T2DM. Besides, although RCTs and epidemiological studies have demonstrated the efficacy of intensive blood glucose control in reducing rates of microvascular complications, its benefits in the prevention of clinically significant LEAD have not been clearly stated. In the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial study, rates of LLA, limb revascularization, lower limb ulceration or death following a peripheral arterial event did not differ between subjects treated with intensive or standard glucose control. 10 In the UK Prospective Diabetes Study (UKPDS), each 1% decrease in HbA1c levels was associated with a 43% reduction of the risk of LLA and LEAD-related death, but the benefit did not persist during the post-trial observational period. 36 Concerning pharmacological strategies, a post-hoc analysis of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial showed a lower incidence of LEAD among patients treated with insulin-sensitising medications (i.e. thiazolidinedione, metformin) as compared with those under insulinproviding therapies (i.e. insulin, sulfonylureas, repaglinide, nateglinide). 37 A series of trials demonstrated a beneficial effect of some of the glucagon-like peptide-1 (GLP-1) receptor agonists on CV risk. The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial, for example, found that semaglutide was associated with a reduction of 35% in coronary and peripheral revascularizations, but no specific data were available regarding lower limb procedures. 38 In patients with diabetic foot, a recent post-hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial showed lower risks of LLA with liraglutide compared with placebo, 39 but no difference was found between groups in terms of revascularization rates. In the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial, on the other hand, the incidence of LEAD was similar between patients treated with exenatide or placebo. 40 Remarkably, some studies suggested an association between some sodium glucose cotransporter 2 (SGLT2) inhibitors and the risk of LLA. Nonetheless, a recent real-life investigation in the USA failed to demonstrate this association, 41 while the secondary analysis of the (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial found similar rates of LLA with empaglifozin compared with placebo. 42 Taking into account these aspects, the 2019 ESC guidelines on diabetes, pre-diabetes and CV diseases developed in collaboration with the European Association for the Study of Diabetes (EASD) recommends the use of SGLT2 inhibitors or GLP-1 receptor agonists with proven CV benefit as part of glycaemic management among patients with T2DM who have established atherosclerotic CV disease, including LEAD. 43 In particular, among GLP-1 receptor agonists, the evidence of benefit was found to be strongest for liraglutide, favourable for semaglutide and less certain for exenatide. For the SGLT2 inhibitors, the evidence is modestly stronger for empagliflozin than canagliflozin, which also showed some benefit in terms of CV profile, as compared with placebo. 44 Lipid-lowering therapy. Several observational studies and RCTs showed that statin therapy results in a reduction in the rate of CV events and total mortality, irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all-cause mortality. 45 Additionally, the REduction of Atherothrombosis for Continued Health (REACH) Registry showed that the use of such medications in subjects with LEAD is associated with a 17% decrease of the rate of CV events, 46 with an 18% lower rate of adverse limb outcomes, including peripheral revascularization and amputations. 46 Of note, although percentages of diabetic patients with CV disease reaching LDL targets increased over time, this goal was not achieved in several cases. 47 In general, the safety profile of statins is acceptable and their administration is advised in all patients with symptomatic LEAD, including those with T2DM. Combination therapy with ezetimibe in some subjects may also be beneficial.
Compared to ezetimibe, evolocumab, a monoclonal antibody inhibiting proprotein convertase subtilisin/ kexin type 9 (PCSK9), was found to have a higher lipid-lowering efficacy in the diabetic population. 48 Furthermore, the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study demonstrated the additional benefits of this drug, in reducing the CV risk as compared with patients treated with statins alone. 49 These effects remained significant also in the subgroup of 1505 patients with LEAD, but further evidence is still needed.
Antihypertensive treatment. In patients with LEAD, the available data on the effectiveness of good BP control mainly come from the INternational VErapamil-SR/ Trandolapril STudy (INVEST) study. 50 Precautions should be taken to avoid a decrease in SBP below 110-120 mm Hg, since the trial suggested that CV risk increases if BP is too low, which is known as the 'J-curve' phenomenon. The J-shape reflects an increased risk at high BP levels, decreasing in parallel with the reduction in BP values to a nadir, below which a further reduction of BP increases the risk again.
Diuretics, beta-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs), and their combinations are all feasible. In the above-mentioned study, no difference was observed in terms of CV risk modification between treatment with verapamil plus trandolapril, and atenolol plus hydrochlorothiazide. The Heart Outcomes Prevention Evaluation (HOPE) and Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) studies have also shown that ACEIs and ARBs significantly reduce CV events in subjects with arterial disease, irrespective of hypertension status. 51 Therefore, these two classes of antihypertensive drugs are also recommended for secondary prevention in this setting, even in the presence of CLTI, where their use is associated with a decrease in MACEs and total mortality, with no adverse effect on the affected limb. 52 Antithrombotic treatment. The main purpose of the antithrombotic therapy in patients with LEAD is to prevent MACEs and MALEs. The choice to introduce such treatment will depend on the presence of LEAD-related symptoms, including typical or atypical intermittent claudication, resting ischaemic pain, ischaemic ulcers or a history of lower extremity revascularization. The presence of coronary artery disease or concomitant cerebrovascular disease also influences the choice of antithrombotic therapy.
Current ESC guidelines recommend the use of single antiplatelet therapy in asymptomatic patients with a history of CVD and in those with symptomatic LEAD (preferably clopidogrel, especially in stable disease) while treatment is not indicated in asymptomatic patients without coronary or cerebrovascular involvement. 25 One study on the general population (with an ABI < 0.95), 53 and another on patients with T2DM (with an ABI < 1.0), 54 revealed no benefit with aspirin in asymptomatic subjects, as compared with placebo. In symptomatic patients, the most convincing evidence for the protective role of aspirin against MACEs comes from the 'Antithrombotic Trialists Collaboration': in 6200 patients, aspirin significantly reduced MACE rates compared with controls (6.4 vs 7.9%). 55 In a post-hoc analysis of the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study, clopidogrel was superior to aspirin at three years in the subgroup of symptomatic patients, with a significant reduction in both CV mortality and MACEs. Similar benefits were found in the subgroup of subjects with T2DM. 56 Of note, the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial study, which included 7470 patients with LEAD plus coronary artery disease or clinically manifest cerebrovascular disease, showed that rivaroxaban 2.5 mg combined with aspirin significantly decreased the occurrence of MACEs, lower limb ischaemia and major amputations compared with aspirin alone. 57 This pharmacological association may provide future therapeutic perspectives in diabetic patients with LEAD.
Surgical or endovascular revascularization
To date, revascularization indications for LEAD do not differ according to the T2DM status, and neither do the therapeutic strategies (i.e. bypass surgery or endovascular therapy) which is in contrast to the management of coronary artery disease. According to current guidelines, revascularization is mandatory as far as possible in the case of CLTI, while it can also be considered in case of disabling intermittent claudication, particularly if not improving after medical and exercise therapy. 25 Contrasting findings were reported concerning perioperative outcomes in patients with T2DM undergoing revascularization. Recent studies have shown similar peri-and post-operative mortality in subjects with T2DM compared with those without the disease. Nonetheless, the former had a higher risk of incomplete wound healing and major amputation, prolonged length of hospital stay and more frequent readmission. 58 The different options of revascularization largely depend on several factors, such as anatomical location and extension of arterial lesions, patients' general condition and comorbidities, as well as surgeon experience. Treating distal lesions (i.e. infra-popliteal) is particularly challenging, and such an anatomical location has been reported to be more frequent in patients with concomitant DM than in those without the disease. Current ESC and European Society for Vascular Surgery (ESVS) guidelines recommend endovascular therapy as the first choice for infra-popliteal stenotic lesions and short occlusions, while bypass with an autologous vein graft may be discussed for long occlusions. 25 However, endovascular therapy can be tried in patients with long occlusions if the surgical risk is considered as high, or in the absence of an autologous vein.
Conclusions
Regular and appropriate screening for LEAD in diabetic patients is recommended. Affected subjects should be managed with optimal medical treatment including careful management of the different CV risk factors through a healthy lifestyle, a regular and supervised physical activity, and the administration of lipid-lowering, antidiabetic and (if indicated) antihypertensive and antithrombotic drugs. However, high quality research is needed, in order to advance knowledge in the pathways and natural history of LEAD in T2DM and, consequently, offer guidance for proper and effective management.
